Proteomic and antibody production and characterization
Active Awarded Last action
- Contract number
- 75N91024F00029
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $10,477,563
Award facts
- Contract value 100% obligated
- $10,477,563.00 Current and potential, with all options
- Completion date 43% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Terminate for Convenience | -$241,847 | |
| Terminate for Convenience | $0 | |
| Original award | $10,719,410 |
About this award
The National Cancer Institute (NCI) awarded a $10.48 million delivery order contract to Leidos Biomedical Research Inc. for proteomic and antibody production and characterization services. This cost-plus-fixed-fee delivery order, which commenced on September 1, 2024, and is scheduled for completion by August 31, 2029, does not utilize a set-aside designation and will be performed at the contractor's Frederick, Maryland location. Leidos Biomedical Research Inc. operates as a Federally Funded Research and Development Center (FFRDC) subsidiary of Leidos Holdings, Inc., providing comprehensive biomedical research and facilities support to the NCI and broader National Institutes of Health enterprise.
The contract supports NCI's research mission through specialized scientific and technical capabilities in protein analysis and immunological research. Leidos Biomedical Research Inc. brings demonstrated expertise in complex biomedical research including gene therapy development, infectious disease investigation, clinical trial support, and advanced laboratory analysis. The contractor's track record includes multi-year, cost-plus-fixed-fee delivery orders involving sophisticated genetic and immunological investigations, positioning it to deliver the proteomic analysis and antibody development services required by this award. The contract aligns with the Cancer Institute's research infrastructure and scientific support objectives within the federal biomedical research portfolio.
Quick answers
Who was awarded contract 75N91024F00029?
75N91024F00029 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 1, 2024.
How much is contract 75N91024F00029 worth?
The government has obligated $10,477,563 on 75N91024F00029.
Is contract 75N91024F00029 an order under another contract?
Yes. 75N91024F00029 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91024F00029 competed?
The extent of competition for 75N91024F00029 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award